Graphite Bio, Inc. specializes in developing therapies for severe and life-threatening diseases through gene editing. Its product candidates include GPH101 for sickle cell disease, GPH201 for immunodeficiency syndrome, and GPH301 for Gaucher disease. Founded in 2017 and headquartered in South San Francisco, California, the company was formerly known as Integral Medicines, Inc.